{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-061486","form_type":"8-K","ticker":"BDTX","cik":"0001701541","company_name":"Black Diamond Therapeutics, Inc.","filed_at":"2023-05-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.104273+00:00","generated_at":"2026-06-14T23:50:10.263539+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Black Diamond Therapeutics elects three Class III directors, ratifies auditor at annual meeting","bullets":["David M. Epstein, Wendy L. Dixon, and Kapil Dhingra elected as Class III directors to serve until 2026.","Epstein received 26.4M votes for, 84k withheld; Dixon 19.1M for, 7.3M withheld; Dhingra 20.0M for, 6.4M withheld.","PricewaterhouseCoopers LLP ratified as independent auditor for FY2023 with 31.0M for, 22k against, 18k abstain.","Meeting held virtually May 16, 2023; 31.1M shares represented out of 36.5M outstanding."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-061486","json":"https://secwatch.observer/filing/0001104659-23-061486.json","markdown":"https://secwatch.observer/filing/0001104659-23-061486.md","text":"https://secwatch.observer/filing/0001104659-23-061486.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701541/000110465923061486/0001104659-23-061486-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701541/000110465923061486/tm2315952d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T23:50:10.263539+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a578cb7dc0748bc0e1b6387e5c5ca03f04b98681","claim":"Black Diamond Therapeutics, Inc. shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2023 at the 2023-05-16 meeting.","evidence_excerpt":"Proposal No. 2 The appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified. The results of the ratification were as follows: FOR AGAINST ABSTAIN 31,012,770 22,331 17,856","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701541/000110465923061486/0001104659-23-061486-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-16"}],"fact_type":"shareholder_vote"},{"claim_id":"d627a17ae2de5f159d579c2545fecabe6925934c","claim":"Black Diamond Therapeutics, Inc. shareholders approved Election of three Class III director nominees at the 2023-05-16 meeting.","evidence_excerpt":"Proposal No. 1 David M. Epstein, Wendy L. Dixon and Kapil Dhingra were duly elected to the Board as Class III directors. The results of the election were as follows: CLASS II DIRECTOR NOMINEE FOR WITHHELD BROKER NON- VOTES David M. Epstein 26,357,348 84,077 4,611,532 Wendy L. Dixon 19,131,310 7,310,115 4,611,532 Kapil Dhingra 20,012,773 6,428,652 4,611,532","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701541/000110465923061486/0001104659-23-061486-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-16"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}